Cargando…
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633715/ https://www.ncbi.nlm.nih.gov/pubmed/26449164 http://dx.doi.org/10.1038/ncomms9495 |
_version_ | 1782399252601765888 |
---|---|
author | Hurst, Jacob Hoffmann, Matthias Pace, Matthew Williams, James P. Thornhill, John Hamlyn, Elizabeth Meyerowitz, Jodi Willberg, Chris Koelsch, Kersten K. Robinson, Nicola Brown, Helen Fisher, Martin Kinloch, Sabine Cooper, David A. Schechter, Mauro Tambussi, Giuseppe Fidler, Sarah Babiker, Abdel Weber, Jonathan Kelleher, Anthony D. Phillips, Rodney E. Frater, John |
author_facet | Hurst, Jacob Hoffmann, Matthias Pace, Matthew Williams, James P. Thornhill, John Hamlyn, Elizabeth Meyerowitz, Jodi Willberg, Chris Koelsch, Kersten K. Robinson, Nicola Brown, Helen Fisher, Martin Kinloch, Sabine Cooper, David A. Schechter, Mauro Tambussi, Giuseppe Fidler, Sarah Babiker, Abdel Weber, Jonathan Kelleher, Anthony D. Phillips, Rodney E. Frater, John |
author_sort | Hurst, Jacob |
collection | PubMed |
description | Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication. |
format | Online Article Text |
id | pubmed-4633715 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Pub. Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46337152015-11-25 Immunological biomarkers predict HIV-1 viral rebound after treatment interruption Hurst, Jacob Hoffmann, Matthias Pace, Matthew Williams, James P. Thornhill, John Hamlyn, Elizabeth Meyerowitz, Jodi Willberg, Chris Koelsch, Kersten K. Robinson, Nicola Brown, Helen Fisher, Martin Kinloch, Sabine Cooper, David A. Schechter, Mauro Tambussi, Giuseppe Fidler, Sarah Babiker, Abdel Weber, Jonathan Kelleher, Anthony D. Phillips, Rodney E. Frater, John Nat Commun Article Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following transmission may induce a state of ‘post-treatment control' (PTC) in some patients, in whom viraemia remains undetectable when ART is stopped. Explaining PTC could help our understanding of the processes that maintain viral persistence. Here we show that immunological biomarkers can predict time to viral rebound after stopping ART by analysing data from a randomized study of primary HIV-1 infection incorporating a treatment interruption (TI) after 48 weeks of ART (the SPARTAC trial). T-cell exhaustion markers PD-1, Tim-3 and Lag-3 measured prior to ART strongly predict time to the return of viraemia. These data indicate that T-cell exhaustion markers may identify those latently infected cells with a higher proclivity to viral transcription. Our results may open new avenues for understanding the mechanisms underlying PTC, and eventually HIV-1 eradication. Nature Pub. Group 2015-10-09 /pmc/articles/PMC4633715/ /pubmed/26449164 http://dx.doi.org/10.1038/ncomms9495 Text en Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Hurst, Jacob Hoffmann, Matthias Pace, Matthew Williams, James P. Thornhill, John Hamlyn, Elizabeth Meyerowitz, Jodi Willberg, Chris Koelsch, Kersten K. Robinson, Nicola Brown, Helen Fisher, Martin Kinloch, Sabine Cooper, David A. Schechter, Mauro Tambussi, Giuseppe Fidler, Sarah Babiker, Abdel Weber, Jonathan Kelleher, Anthony D. Phillips, Rodney E. Frater, John Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title_full | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title_fullStr | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title_full_unstemmed | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title_short | Immunological biomarkers predict HIV-1 viral rebound after treatment interruption |
title_sort | immunological biomarkers predict hiv-1 viral rebound after treatment interruption |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633715/ https://www.ncbi.nlm.nih.gov/pubmed/26449164 http://dx.doi.org/10.1038/ncomms9495 |
work_keys_str_mv | AT hurstjacob immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT hoffmannmatthias immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT pacematthew immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT williamsjamesp immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT thornhilljohn immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT hamlynelizabeth immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT meyerowitzjodi immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT willbergchris immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT koelschkerstenk immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT robinsonnicola immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT brownhelen immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT fishermartin immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT kinlochsabine immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT cooperdavida immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT schechtermauro immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT tambussigiuseppe immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT fidlersarah immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT babikerabdel immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT weberjonathan immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT kelleheranthonyd immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT phillipsrodneye immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption AT fraterjohn immunologicalbiomarkerspredicthiv1viralreboundaftertreatmentinterruption |